Table 3 Changes of lipid profile and other biochemical data at 12 weeks after initiating PCSK9 inhibitors treatment
| Â | LDL target non-achiever | LDL target achiever | Total | P value |
|---|---|---|---|---|
N = 91 | N = 120 | N = 211 | ||
Total cholesterol (mg/dL) | − 20.4 (− 28.4, − 6.4) | − 50.9 (− 57.7, − 42.3) | − 36.8 (− 52.9, − 22.2) |  < 0.001 |
LDL-C (mg/dL) | − 29.4 (− 38, − 10.5) | − 71.5 (− 81.8, − 62.2) | − 54.7 (− 73.4, − 33.3) |  < 0.001 |
HDL-C (mg/dL) | 2.3 (− 5.6, 10.3) | 5.9 (− 3.2, 22.2) | 4.5 (− 4.5, 14.9) | 0.030 |
Triglyceride (mg/dL) | 0.8 (− 24.1, 21.8) | − 30.8 (− 42.9, − 7.9) | − 19.5 (− 40.3, 6.1) |  < 0.001 |
Fasting sugar (mg/dL) | 0.5 (− 9.1, 9.4) | − 1.0 (− 12.1, 8.8) | 0.0 (− 10.3, 9.0) | 0.585 |
HbA1C | 0.0 (− 3.4, 1.8) | 0.0 (− 3.2, 3.2) | 0.0 (− 3.3, 1.9) | 0.773 |
AST (U/L) | 3.7 (− 10.0, 11.8) | 0.0 (− 11.7, 18.0) | 0.0 (− 10.3, 15.7) | 0.551 |
ALT (U/L) | 6.4 (− 17.6, 26.3) | − 5.9 (− 19.8, 14.5) | 0.0 (− 18.6, 23.1) | 0.064 |
Creatinine (mg/dL) | 0.0 (− 10.0, 9.8) | − 3.6 (− 12.1, 7.1) | − 1.3 (− 10.9, 7.6) | 0.102 |